CDMO Onboarding Checklist: Six Evidence Gates Before Technology Transfer

For an overseas pharmaceutical partner, the first question is not “Can a CDMO take the project?” It is “What evidence and decisions would be needed before either party can responsibly say yes?” The six gates below are an editorial decision framework drawn from public guidance, not an official regulator-prescribed sequence.

Partial update 2026-10-09: added timeline planning guidance and a matching FAQ. Original publication and full-review dates are retained.

Onboarding versus technology transfer

Onboarding establishes the proposed relationship, scope, responsibilities, information controls and decision route. Technology transfer is a planned, documented transfer of product, process and analytical knowledge between a sending unit and a receiving unit. WHO's 2022 guidance describes project initiation, planning, execution and review/close-out; it also calls for due diligence and a gap analysis before transfer work proceeds. [WHO]

A proposal to onboard a CDMO therefore does not itself establish the receiving site's readiness, target-market eligibility or future commercial outcome. Those conclusions require product-, site-, market- and date-specific evidence.

Six evidence gates for a proposed CDMO onboarding

1. Define the exact scope and disclosure boundary

Record the legal entities, intended product and dosage form, development or commercial stage, target markets and requested activities. State who is proposing to hold product and regulatory responsibilities. Begin with a non-confidential brief; use appropriate confidentiality arrangements before sharing proprietary formulations, full dossiers or detailed process instructions. [WHO]

2. Test receiving-site fit through a documented gap analysis

Compare the sending and receiving units' facilities, equipment, utilities, analytical capability, people and control strategies for the specific product. Record each gap, its quality or regulatory impact, owner and closure evidence. A shared dosage-form label or an equipment list is only a screening clue, not a fit decision. WHO calls for due diligence and gap analysis; its guidance highlights particular attention for sterile products. [WHO]

3. Map knowledge, materials and analytical methods

Identify what must move from the sending unit: process rationale, critical attributes and parameters, historical deviations, specifications, reference standards, samples, methods, materials and training. Agree which items require comparison or transfer studies, rather than assuming a document handoff is sufficient. [WHO]

4. Allocate quality decisions in writing

Define who performs, reviews, approves and communicates deviations, changes, investigations, testing, batch disposition, subcontracting and regulatory notifications. FDA's quality-agreement guidance addresses written allocation of manufacturing activities; EU GMP Chapter 7 addresses outsourced-activity responsibilities. The agreement does not remove each party's applicable legal duties. Apply the rules of the actual target jurisdiction. [FDA] [EU]

5. Approve a staged plan and acceptance criteria

Use a transfer plan or protocol with milestones, responsibilities, predefined acceptance criteria, validation and change-control routes, escalation and stop/go decisions. WHO describes a documented project plan and evidence that the receiving unit can reproducibly perform the transferred process or procedure against agreed specifications. The needed rigor depends on the product lifecycle stage. [WHO]

6. Close the evidence loop before the next commitment

Record what was completed, what remains open, who accepted each result and what conditions govern progression. A gap can be an owned development task, a risk control or a reason to pause; a checklist alone cannot sign off a transfer. Reassess changes in product, site, market, ownership or supply assumptions before relying on an earlier decision. [WHO] [FDA]

How to estimate a CDMO onboarding timeline

There is no universal number of weeks that establishes readiness. A requested start date is a planning input, not evidence that a receiving site can execute the work. The following is an editorial project-planning aid, not a regulator-prescribed timetable or a delivery commitment.

1. Scope and information access: identify the product, site, market and requested activity; agree the non-confidential brief and the route for any later confidential exchange. Record what information is still unavailable and who can release it.
2. Gap assessment: distinguish document review from studies or remediation. Assign each critical gap an owner, closure evidence and a decision date. Equipment changes, material lead times and reference-standard availability should be recorded as dependencies, not hidden in an overall estimate.
3. Execution readiness: agree the method/process work packages, quality responsibilities, available resources and acceptance criteria. Identify what may proceed in parallel and what must wait for an approved result.
4. Stage decision: document completed evidence, open conditions and the authorized decision owner. Keep regulatory review, validation and commercial release milestones separate from an onboarding completion date.

Ask for a milestone-based estimate: “What deliverable closes this stage, who accepts it, what must happen first, and when will the estimate be reviewed?” If the supporting evidence or a critical dependency is missing, retain a conditional estimate rather than announcing a firm supply date.

An API project and a finished sterile injectable project should not inherit the same schedule merely because both use a CDMO. A partner's country, including Switzerland, does not by itself establish the receiving site's readiness or the duration of a European project. Use the actual project and jurisdictional scope.

What to share at first contact

A short non-confidential brief can state the dosage form, broad therapeutic category, current stage, intended markets, proposed services, presentation or scale range, indicative timing and known special handling needs. It can also list unanswered questions. Do not send patient data, full formulas, unpublished technical files or commercial secrets through a first-contact form or email.

For China domestic contract-manufacturing proposals, apply the current NMPA framework to the exact MAH, product, contractor and activity. A general international checklist cannot establish eligibility under a China-specific arrangement. [NMPA]

Frequently asked questions

Primary sources and scope

1. WHO TRS 1044, Annex 4 (2022): technology transfer in pharmaceutical manufacturing
2. U.S. FDA (2016): Contract Manufacturing Arrangements for Drugs—Quality Agreements
3. European Commission: EudraLex Volume 4, Chapter 7—Outsourced Activities
4. NMPA Announcement No. 134 of 2025: Strengthening Supervision and Administration of Contract Manufacturing of Drugs (issued 30 December 2025; English page updated 14 April 2026)

This is a source-based industry decision framework, not legal, regulatory, medical or quality-system advice. It does not claim a named facility's approval, capacity, project acceptance or product availability.